A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182 · tracked via the Priya Life Science USA tracker

Sponsor

Eli Lilly and Company

Phase

Phase 1

Started

2026-09

Last updated

2026-08-26

Condition(s) studied

Healthy VolunteersAlzheimer DiseaseAmyloidPlaque, Amyloid

Investigational drug(s) / intervention(s)

LY4405094LY4405094PlaceboPlaceboFlorbetapir F18Florbetaben F 18

LY4405094: Administered intravenously (IV)

LY4405094: Administered Subcutaneously (SC)

Placebo: Administered IV

Placebo: Administered SC

Florbetapir F18: Administered IV

Florbetaben F 18: Administered IV

Study summary

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study. Exclusion Criteria: * Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094. * Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

Primary outcome measure(s)

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — Baseline up to 25 Weeks

Trial sites (10)

Facility	City	Region
Irvine Clinical Research	Irvine	California
Fortrea Clinical Research Unit	Daytona Beach	Florida
K2 Medical Research - The Villages	Lady Lake	Florida
K2 Medical Research	Maitland	Florida
Charter Research	Orlando	Florida
Progressive Medical Research	Port Orange	Florida
K2 Medical Research - Tampa	Tampa	Florida
Charter Research	The Villages	Florida
Accel Research Sites - NeuroStudies Clinical Research Unit	Decatur	Georgia
QUEST Research Institute	Farmington Hills	Michigan

More Eli Lilly and Company trials in the USA

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Active, not recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein) Starting soon

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease Recruiting

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight Starting soon

Other trials for the same condition

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older Active, not recruiting

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein) Starting soon

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease Recruiting

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07787182 on ClinicalTrials.gov ↗ ← All trials in the USA